May 22, 2019 / 11:09 AM / a month ago

BRIEF-Synlogic Announces Collaboration To Evaluate Synb1891 In Combination With Pd-L1 In Patients With Advanced Solid Tumors

May 22 (Reuters) - Synlogic Inc:

* SYNLOGIC ANNOUNCES CLINICAL COLLABORATION TO EVALUATE SYNB1891 IN COMBINATION WITH PD-L1 CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS

* SYNLOGIC - COLLABORATION WITH ROCHE TO EXPLORE CO'S SYNTHETIC BIOTIC MEDICINE, SYNB1891 IN COMBINATION WITH ROCHE'S PD-L1-BLOCKING CHECKPOINT INHIBITOR ATEZOLIZUMAB

* SYNLOGIC INC - EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA IN SECOND HALF OF 2019 FOR SYNB1891 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below